Meeting
2021 ASCO Annual Meeting
Identification of genetic markers associated with ibrutinib-related cardiovascular toxicity.
Authors
Issam Hamadeh
Department of Hematologic Malignancies and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC
Issam Hamadeh , Ryan Jacobs , Bei Hu , Tamara Kay Moyo , Amy Soni , Steven I. Park , Jai Narendra Patel , Nury Steuerwald , Nilanjan Ghosh
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Chronic Lymphocytic Leukemia (CLL) and Hairy Cell
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 7526)
DOI
10.1200/JCO.2021.39.15_suppl.7526
Abstract #
7526
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
A single-cell multiomics analysis of IRF4 in mediating treatment resistance in ibrutinib-treated chronic lymphocytic leukemia (CLL).
First Author: Alina S. Gerrie
Poster
2023 ASCO Annual Meeting
The impact of population pharmacogenomics and risk allele frequencies on cisplatin-induced peripheral sensory neuropathy (PSN).
First Author: Swetha Nakshatri
Poster
2020 ASCO Virtual Scientific Program
Effect of adding ublituximab to ibrutinib on PFS, ORR, and MRD negativity in previously treated high-risk chronic lymphocytic leukemia: Final results of the GENUINE phase III study.
First Author: Jeff P. Sharman
Poster
2019 ASCO Annual Meeting
Association of single nucleotide polymorphisms within genes in NF-κB, TGF-β, and JNK signaling pathways with the risks of nasopharyngeal carcinoma in Chinese Han.
First Author: Hanyi Zhang